{"id":23217,"date":"2020-05-30T00:48:03","date_gmt":"2020-05-29T22:48:03","guid":{"rendered":"https:\/\/www.hpsj.fr\/?p=19548"},"modified":"2022-05-02T16:14:08","modified_gmt":"2022-05-02T14:14:08","slug":"le-ghpsj-annonce-des-resultats-tres-encourageants-dune-biotherapie-anti-interleukine-1-anakinra-dans-la-prise-en-charge-des-formes-severes-de-covid-19","status":"publish","type":"post","link":"https:\/\/devhml.givememore.net\/le-ghpsj-annonce-des-resultats-tres-encourageants-dune-biotherapie-anti-interleukine-1-anakinra-dans-la-prise-en-charge-des-formes-severes-de-covid-19\/","title":{"rendered":"Le GHPSJ annonce des r\u00e9sultats tr\u00e8s encourageants d\u2019une bioth\u00e9rapie anti-interleukine-1 (Anakinra) dans la prise en charge des formes s\u00e9v\u00e8res de COVID-19"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\" id=\"le-groupe-hospitalier-paris-saint-joseph-annonce-des-resultats-tres-encourageants-d-une-biotherapie-anti-interleukine-1-anakinra-dans-la-prise-en-charge-des-formes-severes-de-covid-19\">Le Groupe hospitalier Paris Saint-Joseph annonce des r\u00e9sultats tr\u00e8s encourageants d\u2019une bioth\u00e9rapie anti-interleukine-1 (Anakinra) dans la prise en charge des formes s\u00e9v\u00e8res de COVID-19<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Une \u00e9quipe m\u00e9dicale multidisciplinaire du Groupe Hospitalier Paris Saint-Joseph (GHPSJ) a d\u00e9voil\u00e9 aujourd\u2019hui dans la revue <strong><em>The<\/em> <em>Lancet Rheumatology<\/em><\/strong> l\u2019\u00e9valuation d\u2019une strat\u00e9gie th\u00e9rapeutique propos\u00e9e aux patients admis pour une forme s\u00e9v\u00e8re de COVID-19, en situation de d\u00e9t\u00e9rioration majeure de leur fonction respiratoire et risquant \u00e0 court terme un transfert en milieu de soins intensifs (<span style=\"text-decoration: underline\"><a href=\"http:\/\/www.thelancet.com\/journals\/lanrhe\/article\/PIIS2665-9913(20)30164-8\/fulltext\" target=\"_blank\" rel=\"noopener noreferrer\">http:\/\/www.thelancet.com\/journals\/lanrhe\/article\/PIIS2665-9913(20)30164-8\/fulltext<\/a><\/span><u>)<\/u>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En comparaison avec un groupe contr\u00f4le historique de 44 patients pris en charge dans la m\u00eame institution, l\u2019administration pendant 10 jours d\u2019une bioth\u00e9rapie ciblant l\u2019interleukine 1, l\u2019<strong>Anakinra<\/strong> (Kineret<sup>\u00e2<\/sup>), \u00e0 un groupe de 52 patients atteints d\u2019une forme grave de COVID-19 a permis une r\u00e9duction statistiquement significative du risque de d\u00e9c\u00e8s et de passage en r\u00e9animation pour assistance respiratoire par ventilation m\u00e9canique. En effet, <strong>25%<\/strong> des patients trait\u00e9s avec l\u2019Anakinra ont d\u00fb \u00eatre transf\u00e9r\u00e9s en r\u00e9animation ou sont d\u00e9c\u00e9d\u00e9s alors que, dans le groupe contr\u00f4le, ce pourcentage a atteint <strong>72,7%<\/strong>. Par ailleurs, de r\u00e9els b\u00e9n\u00e9fices m\u00e9dicaux sont apparus pour le groupe recevant de l\u2019Anakinra, avec une <strong>diminution rapide des besoins en oxyg\u00e8ne<\/strong>, observ\u00e9e au bout de 7 jours de traitement. L\u2019Anakinra est un m\u00e9dicament bien connu des rhumatologues, utilis\u00e9 initialement dans le traitement d\u2019une maladie rhumatismale inflammatoire, la polyarthrite rhumato\u00efde, avec un excellent profil de tol\u00e9rance.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le choix de l\u2019Anakinra s\u2019est impos\u00e9 au terme de r\u00e9unions multidisciplinaires impliquant rhumatologues, internistes, pneumologues, pharmaciens et urgentistes, en raison d\u2019une part de son m\u00e9canisme d\u2019action qui semblait r\u00e9pondre \u00e0 la physiopathologie de l\u2019orage cytokinique, et d\u2019autre part en raison de sa cin\u00e9tique d\u2019action rapide, adapt\u00e9e \u00e0 ces formes cliniques d\u2019\u00e9volution ultra-rapide.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u00ab <em>Le suivi prospectif et l\u2019analyse des r\u00e9sultats ont \u00e9t\u00e9 rendus possibles par la mise en place d\u00e8s la mi-mars d\u2019un suivi de cohorte prospectif par le centre de recherche clinique du GHPSJ, ce qui a permis une surveillance \u00e9troite de la tol\u00e9rance et de l\u2019efficacit\u00e9 de l\u2019ensemble des th\u00e9rapeutiques qui ont \u00e9t\u00e9 propos\u00e9es \u00e0 titre compassionnel pour les patients hospitalis\u00e9s pour COVID-19 <\/em>\u00bb, rappelle le <strong>Docteur H\u00e9l\u00e8ne Beaussier<\/strong>, pharmacienne et responsable du <strong>Centre de Recherche Clinique<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le <strong>Professeur Jean-Jacques Mourad, <\/strong>chef du service de M\u00e9decine Interne<strong>, <\/strong>&nbsp;rappelle le contexte : \u00ab <em>En l\u2019absence d\u2019acc\u00e8s \u00e0 des essais th\u00e9rapeutiques incluant des m\u00e9dicaments immunomodulateurs pour nos patients, la d\u00e9cision que nous avons prise de proposer l\u2019Anakinra, selon des crit\u00e8res de gravit\u00e9 d\u00e9cid\u00e9s de mani\u00e8re consensuelle et a priori, a rapidement chang\u00e9 le visage de la maladie en salle. Le b\u00e9n\u00e9fice \u00e9tait \u00ab palpable \u00bb au quotidien<\/em> \u00bb.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>\u00ab&nbsp;Les r\u00e9sultats de notre \u00e9tude sugg\u00e8rent que l\u2019Anakinra est un traitement efficace dans la phase hyper-inflammatoire du COVID-19, situation qui comporte un risque \u00e9lev\u00e9 de transfert en milieu de soins intensifs, contrairement \u00e0 la forme b\u00e9nigne, heureusement plus fr\u00e9quente, de la maladie. Le profil de tol\u00e9rance de l\u2019anakinra a \u00e9t\u00e9 satisfaisant&nbsp;: nous avons uniquement constat\u00e9 une augmentation des transaminases h\u00e9patiques chez moins de 15% des patients sous Anakinra, sans cons\u00e9quence clinique apparente. S\u2019agissant d\u2019une maladie \u00e0 caract\u00e8re syst\u00e9mique, c\u2019est-\u00e0-dire susceptible de toucher plusieurs secteurs distincts de l\u2019organisme, toutes ses cons\u00e9quences, notamment thromboemboliques, n\u2019ont pu \u00eatre \u00e9valu\u00e9es aussi pr\u00e9cis\u00e9ment que la fonction respiratoire ou la mortalit\u00e9. A ce stade, nous sommes convaincus que ce traitement doit \u00eatre test\u00e9 sur un plus grand nombre de patients hospitalis\u00e9s en phase s\u00e9v\u00e8re du COVID-19&nbsp;\u00bb <\/em>commente le <strong>Docteur Gilles Hayem<\/strong>, chef du service de rhumatologie.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Le GHPSJ a accueilli plus de 1700 patients atteints par le COVID-19 au sein de son service d\u2019accueil des urgences (SAU). Plus de 220 lits d\u2019hospitalisation traditionnelle et 70 de r\u00e9animation ont \u00e9t\u00e9 mobilis\u00e9s au pic de la vague \u00e9pid\u00e9mique. Plus de 900 patients ont \u00e9t\u00e9 hospitalis\u00e9s sur les deux sites (H\u00f4pital Saint-Joseph, H\u00f4pital Marie Lannelongue), dont 120 en r\u00e9animation. La mortalit\u00e9 hospitali\u00e8re pour ces patients a \u00e9t\u00e9 de 10,2% en secteur d\\&rsquo;hospitalisation traditionnelle et de 22% en r\u00e9animation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Ces r\u00e9sultats encourageants permettent d\u00e8s \u00e0 pr\u00e9sent de redonner <strong>espoir<\/strong> aux populations expos\u00e9es, ainsi qu\u2019aux \u00e9quipes soignantes qui auront \u00e0 les prendre en charge.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><span style=\"text-decoration: underline\"><strong><a href=\"https:\/\/devhpsj.givememore.net\/wp-content\/uploads\/2020\/05\/CP-AnaCOVID-final.pdf\" target=\"_blank\" rel=\"noopener noreferrer\">Lire le communiqu\u00e9 de presse<\/a><\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lire le communiqu\u00e9 de presse<\/p>\n","protected":false},"author":25,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"disabled","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[18],"tags":[],"etablissements":[],"class_list":["post-23217","post","type-post","status-publish","format-standard","hentry","category-presse"],"acf":[],"author_meta":{"display_name":"usersync","author_link":"https:\/\/devhml.givememore.net\/author\/usersync\/"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/devhml.givememore.net\/category\/presse\/\" class=\"advgb-post-tax-term\">Presse<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Presse<\/span>"]}},"comment_count":0,"relative_dates":{"created":"Publi\u00e9 6 ans il y a","modified":"Mis \u00e0 jour 4 ans il y a"},"absolute_dates":{"created":"Publi\u00e9 le 30 mai 2020","modified":"Mise \u00e0 jour le 2 mai 2022"},"absolute_dates_time":{"created":"Publi\u00e9 le 30 mai 2020 0 h 48 min","modified":"Mise \u00e0 jour le 2 mai 2022 16 h 14 min"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/posts\/23217","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/comments?post=23217"}],"version-history":[{"count":1,"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/posts\/23217\/revisions"}],"predecessor-version":[{"id":23218,"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/posts\/23217\/revisions\/23218"}],"wp:attachment":[{"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/media?parent=23217"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/categories?post=23217"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/tags?post=23217"},{"taxonomy":"etablissements","embeddable":true,"href":"https:\/\/devhml.givememore.net\/api\/wp\/v2\/etablissements?post=23217"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}